About Dr Reddys Laboratories Ltd
Dr Reddys Laboratories a prominent global pharmaceutical company headquartered in Hyderabad, India. Founded in 1984, it is a leader in affordable medicines, offering a wide array of active pharmaceutical ingredients (APIs), generics, branded generics, and biosimilars across key therapeutic areas like oncology, cardiovascular care, and diabetology.
Founded
1984
CEO
Satish Reddy
Employees
42,487
HQ
Hyderabad, India
Finished Products
1Sales
₹1,04,618.10Cr2License Fees
₹2,591.90Cr3Sale of Spent Chemicals
₹232.00Cr4Services
₹197.30Cr5Scrap Sales
₹129.50Cr6Other Operating Revenues
₹80.00CrRaw Materials
1Cost of Material Consumed
₹10,785.40Cr2Purchase of Traded Goods
₹8,841.60Cr30) Octa
₹3,799.70CrAbout Dr Reddys Laboratories Ltd
Dr Reddys Laboratories a prominent global pharmaceutical company headquartered in Hyderabad, India. Founded in 1984, it is a leader in affordable medicines, offering a wide array of active pharmaceutical ingredients (APIs), generics, branded generics, and biosimilars across key therapeutic areas like oncology, cardiovascular care, and diabetology.
Founded:1984
CEO:Satish Reddy
Employees:42,487
HQ:Hyderabad, India
Finished Products
1Sales
₹1,04,618.10Cr2License Fees
₹2,591.90Cr3Sale of Spent Chemicals
₹232.00Cr4Services
₹197.30Cr5Scrap Sales
₹129.50Cr6Other Operating Revenues
₹80.00CrRaw Materials
1Cost of Material Consumed
₹10,785.40Cr2Purchase of Traded Goods
₹8,841.60Cr30) Octa
₹3,799.70CrPrice Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹1,415
52W Low
₹1,101
Volume486.54K
Avg VolumeN/A
Beta0.53
Dividend Yield0.69%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
30.44x
Valuation
P/B Ratio
2.55x
Valuation
EPS
₹38.14
Valuation
Dividend Yield
0.69%
Valuation
ROE
11.07%
Profitability
ROCE
12.54%
Profitability
Revenue by Segment
Contribution & growth by business line
Global Generics
+3.3%88.9%
₹29,946 Cr
PSAI
+2.7%10.5%
₹3,540.2 Cr
Others
-0.5%0.6%
₹214 Cr
Geographical Revenue Split
Domestic vs international exposure
Domestic
19.2%
International
80.8%
Others35.3%
United States35.1%
India19.2%
Russia10.4%
Strategic Relations
Collaborations, joint ventures & subsidiaries
D
Debiopharm
Switzerland
0.00% stakeV
Viral Therapeutics Inc
United States
0.00% stakeForensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.20x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
6.4%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.